These organizations hope to connect with attendees at the event, sharing clinical research ideas and innovations in sessions and the virtual exhibit hall.
The CRO is offering an expanded range of post-authorization solutions designed to help developers with treatments and vaccines in their product pipeline
The free Patient-Centric Trial Development Toolkit is aimed toward helping sites and sponsors identify and minimize risks in rare-disease clinical studies.
The CRO is working with PWNHealth and Fulgent Genetics to enhance its monitoring program, including the addition of at-home COVID-19 testing capabilities.
The head of the CRO’s Global Center of Excellence for Decentralized Clinical Trial Strategy outlines key developments in 2020, and keys to success in 2021.
This month’s news about industry hires, promotions, acquisitions and other events includes Signant, PRA, Lonza, Bora Pharmaceuticals and other top firms.
PRA Health Sciences’ wholly-owned subsidiary, Symphony Health, has launched a ‘first of its kind’ national market measurement solution integrating prescriber, patient, and payer insights.
Biopharmaceutical companies are increasingly relying on CROs in Japan, says an executive with PRA, which recently established a new subsidiary in the country.
The industry group recently announced its first technology standard, which addresses operational data exchange in an aim to improve information sharing between sponsors and CROs.
PRA Health Sciences has launched a new site network focused on improving pediatric clinical development and access to novel medicines in this special patient population.
PRA Health Sciences is looking at and assessing various opportunities using real world data – as the company has become reliant on data as part of its clinical process, says CEO.
PRA Health Sciences’ Q2 revenue is up 35%, as the CRO accelerates integration plans with Symphony Health and predicts an increase in staff towards the end of the year.
Transitioning to a single strategic contract research organization (CRO) reduced Bayer’s administrative burden, but the restructuring was met with some resistance, said the firm.
CROs (contract research organizations) continue to collaborate with sponsors on more clinical trials in the US, though the largest companies, such as Quintiles, Parexel and PPD, are working on a much larger share of the research as collaborators than...
In another sign that early phase research demand is picking up, North Carolina-based CRO PRA Health Sciences (PRA) is increasing its Phase I clinical footprint in the US and Russia.
Between May 2013, when Quintiles went public, and this week, newly public companies’ stocks in the biopharma outsourcing space have all seen their prices rise by more than 35%.
Parexel’s future course may depend on the outlook of competing CROs (contract research organizations), a couple of which could potentially go public in the near future, Ingo Bank, SVP and CFO of Parexel, said Wednesday at the Baird 2014 Healthcare Conference.
